Research Topics
Species | G RemingtonSummaryAffiliation: Centre for Addiction and Mental Health Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Rational pharmacotherapy in early psychosisGary Remington
Medical Assessment Program for Schizophrenia, Centre for Addiction and Mental Health, 250 College Street, Totonto, Ontario M5T 1R8, Canada
Br J Psychiatry Suppl 48:s77-84. 2005..An increased focus in research specific to first-episode schizophrenia has provided a rapidly growing body of evidence that can be directly translated to clinical practice...
Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trialGary Remington
Department of Psychiatry, University of Toronto, Toronto, Canada
J Clin Psychopharmacol 32:95-9. 2012....
SB-277011 GlaxoSmithKlineG Remington
Center for Addiction and Mental Health, Toronto, Ontario, Canada
Curr Opin Investig Drugs 2:946-9. 2001....
Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatmentGary Remington
University of Toronto, Toronto, Ontario, Canada
Expert Rev Neurother 11:589-607. 2011..This shift in thinking has important theoretical implications from the standpoint of etiology and pathophysiology, but also clinically in terms of treatment and drug development...
"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trialGary Remington
Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada
J Clin Psychiatry 72:1042-8. 2011..Based on a better understanding of the brain kinetics of antipsychotics, we have proposed a variation of this approach, "extended" dosing, which allows for intermittent but regular dosing...
Antipsychotic dosing: how much but also how often?Gary Remington
Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophr Bull 36:900-3. 2010..Does this mean we need to (or should) administer antipsychotics at least daily? There is a body of evidence challenging this long-established clinical axiom...
Progress in defining optimal treatment outcome in schizophreniaGary Remington
Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
CNS Drugs 24:9-20. 2010..To this end, the field has now embraced a recovery model that is seen as a process, multidimensional and individualized, rather than dichotomous and symptom driven...
Tardive dyskinesia: eliminated, forgotten, or overshadowed?Gary Remington
Faculty of Medicine, University of Toronto, Ontario, Canada
Curr Opin Psychiatry 20:131-7. 2007..The present review focuses on atypical antipsychotics and tardive dyskinesia...
The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophreniaGary Remington
Department of Psychiatry, University of Toronto, Toronto, Canada
Schizophr Res 90:229-37. 2007..More sophisticated measurement tools such as MEMS may assist us in better understanding how level and pattern of antipsychotic noncompliance, factors that at present remain poorly understood, impact on symptom exacerbation...
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidoneGary Remington
Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ont M5T 1R8, Canada
Am J Psychiatry 163:396-401. 2006..The present study used positron emission tomography (PET) to evaluate its dopamine D(2) binding profile at doses of 25, 50, or 75 mg administered every 2 weeks...
Augmentation strategies in clozapine-resistant schizophreniaGary Remington
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
CNS Drugs 19:843-72. 2005..A priori, an endpoint needs to be established and the trial discontinued unless results firmly support added benefits...
Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetGary Remington
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Ont
J Psychiatry Neurosci 28:275-84. 2003..The precise degree of these differences and the underlying mechanisms remain unclear, however. The direction new antipsychotic development takes will undoubtedly hinge on answers to these questions...
The crossover approach to switching antipsychotics: what is the evidence?Gary Remington
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
Schizophr Res 76:267-72. 2005..The existing data therefore argue against the position that a crossover approach in switching antipsychotics represents a 'safer' means of preventing clinical deterioration during the switch...
Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover studyG Remington
Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario, Canada
J Clin Psychopharmacol 21:440-4. 2001..Clomipramine did not seem more effective on a measure of stereotypy, nor was it better tolerated...
The use of pharmacotherapy in the prodrome of schizophreniaGary Remington
Department of Psychiatry, University of Toronto, Toronto, Canada
CNS Spectr 9:579-86. 2004..We now have a limited number of published reports addressing this topic and these are reviewed here...
Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitationsGary Remington
Department of Psychiatry, University of Toronto, Canada
Pharmacol Biochem Behav 100:86-9. 2011..As well, strategies in dissolving olanzapine to diminish oxidation are discussed...
Antipsychotic dosing patterns for schizophrenia in three treatment settingsG Remington
Department of Psychiatry, University of Toronto, Ontario, Canada
Psychiatr Serv 52:96-8. 2001..8 mg). A greater proportion of patients at the provincial hospital received conventional antipsychotics than novel antipsychotics or depot antipsychotics, and a greater proportion received more than one antipsychotic...
Alterations of dopamine and serotonin transmission in schizophreniaGary Remington
Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada
Prog Brain Res 172:117-40. 2008..At present, there is particular interest in the 5-HT(1A), 5-HT(2C), 5-HT(6) and 5-HT(7) receptors as the search for improved pharmacological treatments for schizophrenia continues...
5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigationS Kapur
Schizophrenia Division, Clarke Institute of Psychiatry, Toronto, Ont, Canada
Am J Psychiatry 155:921-8. 1998..The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses...
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancyS Kapur
Department of Psychiatry, University of Toronto, Ontario
Arch Gen Psychiatry 57:553-9. 2000..The following study was undertaken to explore these effects across the clinical dose range and relate this information to its clinical profile...
PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophreniaS Kapur
Schizophrenia Division, Clarke Institute of Psychiatry, University of Toronto, Canada
Am J Psychiatry 154:1525-9. 1997..The purpose of this study was to document loxapine's 5-HT2 and D2 receptor occupancy in vivo in patients with psychoses...
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET studyS Kapur
PET Centre, Clarke Institute of Psychiatry, Toronto, Ont, Canada
Am J Psychiatry 153:948-50. 1996..The purpose of this study was to determine the dopamine D2 receptor occupancy induced by low-dose haloperidol treatment in a prospective trial...
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophreniaS Kapur
The Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, ON, Canada
Am J Psychiatry 156:286-93. 1999..The purpose of this study was to compare the D2 and serotonin 5-HT2 receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens...
Atypical antipsychotics: new directions and new challenges in the treatment of schizophreniaS Kapur
Schizophrenia Program, PET Centre, CAMH, Toronto, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8
Annu Rev Med 52:503-17. 2001..e. positive, negative, cognitive, and affective) with more selective drugs that can be combined and individually titrated to the needs of each patient...
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PETG Remington
Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ontario, Canada
J Clin Psychiatry 60:15-9. 1999..Combined serotonin-2/dopamine-2 (5-HT2/D2) antagonism represents one such model, and we now have PET evidence available that can be extrapolated to our understanding and clinical use of both conventional and novel antipsychotics...
Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapineS Kapur
PET Centre, Clarke Division, CAMH, Toronto, ONT Canada
Am J Psychiatry 158:311-4. 2001....
Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficitsG Foussias
Centre for Addiction and Mental Health, and Department of Psychiatry, University of Toronto, 250 College St, Toronto, Ontario, Canada M5T 1R8
Schizophr Res 132:24-7. 2011..These findings further suggest a fundamental role for motivational deficits in predicting functional outcomes in schizophrenia...
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficientS Kapur
Schizophrenia Program, University of Toronto, Toronto, Canada
Biol Psychiatry 50:873-83. 2001....
Pharmacotherapy of first-episode schizophreniaG Remington
Department of Psychiatry, University of Toronto, Canada
Br J Psychiatry Suppl 172:66-70. 1998..A growing interest in first-episode schizophrenia reflects the belief that this line of investigation will lead to further developments regarding schizophrenia's aetiology, course and outcome...
Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the benchS Kapur
PET Centre, Centre for Addiction and Mental Health, Toronto, ON
Can J Psychiatry 45:241-6. 2000..We exemplify how this dosing confounder could lead to inappropriate conclusions. Data from the bedside translated to the bench--using D2 occupancy as a mediating variable--will lead to more valid animal models...
Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychoticsG Remington
Schizophrenia and Continuing Care Program, Clarke Division, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada
Prog Neuropsychopharmacol Biol Psychiatry 25:363-9. 2001....
Atypical antipsychotics: are some more atypical than others?G Remington
Schizophrenia Program, Centre for Addiction and Mental Health, Clarke Division, 250 College Street, Toronto, Ontario, Canada M5T 1R8
Psychopharmacology (Berl) 148:3-15. 2000..The precise pharmacologic mechanisms underlying "atypicality" remain unclear, but several conceptual frameworks are highlighted that characterize, and perhaps differentiate, these newer agents...
Conventional versus novel antipsychotics: changing concepts and clinical implicationsG Remington
Clarke Institute of Psychiatry, University of Toronto, Ont
J Psychiatry Neurosci 24:431-41. 1999..Future research should involve longer clinical trials, given the long periods needed to establish efficacy, and should address many remaining questions about the novel agents...
Significant dissociation of brain and plasma kinetics with antipsychoticsJohannes Tauscher
Schizophrenia PET program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
Mol Psychiatry 7:317-21. 2002..Our results question the current reliance on plasma kinetics as the main basis for dosing regimens of antipsychotics. Studies of brain kinetics may provide a sounder basis for determining dosing schedules of psychotropic medications...
Motivational deficits as the central link to functioning in schizophrenia: a pilot studyG Foussias
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Schizophr Res 115:333-7. 2009..This suggests that motivational deficits are the central link between negative symptoms and functional impairment in schizophrenia...
Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampusA Baskys
Department of Physiology, University of Toronto, Ont, Canada
Eur J Pharmacol 235:305-7. 1993..These data suggest that haloperidol and loxapine may act by enhancing excitatory synaptic transmission in some areas of the brain, and that novel antipsychotic clozapine differs in its mechanism of action...
Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatographyS W Cheung
Psychopharmacology Unit, Clarke Institute of Psychiatry, Toronto, Canada
J Chromatogr 564:213-21. 1991..As 8-hydroxy metabolites possess only weak dopamine-D2 blocking activity, the final neuroleptic property of loxapine may be affected significantly by metabolic polymorphism...
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patientsC C Zai
Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Pharmacogenomics J 9:168-74. 2009..This study suggests that DRD4 may be involved in TD in the Caucasian population, although further replication studies are needed...
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?Peter Turrone
Institute of Medical Science, University of Toronto, Toronto, Ont, Canada
Neurosci Biobehav Rev 26:361-80. 2002..These findings are consistent with the possibility that total D(2) occupancy, as well as 'transience' of receptor occupation, may be important in the development of late-onset antipsychotic-induced dyskinetic syndromes...
How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experienceCarolyn S Dewa
Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Clin Ther 24:1466-76. 2002..The introduction of new antipsychotic agents in the past decade has helped alter the treatments available to 2 vulnerable populations-those with schizophrenia and related psychotic conditions and elderly individuals with dementia...
Body mass index, waist circumference and quality of life in individuals with schizophreniaGuy Faulkner
Faculty of Physical Education and Health, University of Toronto, Ontario, Canada M5S 2W6
Schizophr Res 90:174-8. 2007..The primary objective was to examine the differential relationship between waist circumference, body mass index, and self-reported quality of life in patients with schizophrenia...
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patientsClement C Zai
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Int J Neuropsychopharmacol 10:639-51. 2007..047). Taken together, the present study suggests that DRD2 may be involved in TD in the Caucasian population, although further studies are warranted...
Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?Gary Remington
Am J Psychiatry 163:1132-4. 2006
Early use of clozapine for poorly responding first-episode psychosisOfer Agid
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
J Clin Psychopharmacol 27:369-73. 2007....
Clozapine-induced hypersalivation: a review of treatment strategiesSanjeev Sockalingam
Department of Psychiatry, University of Toronto, Ontario
Can J Psychiatry 52:377-84. 2007..The purpose of this review is to provide an understanding of CIH, specifically, its pathophysiology, measurement, and the evidence for CIH treatment alternatives...
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effectsMonica Hazra
Am J Psychiatry 165:396-7; author reply 397-8. 2008
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophreniaHiroyuki Uchida
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
J Clin Psychiatry 69:1281-6. 2008..The objective of this positron emission tomography (PET) study was to examine the striatal dopamine D(2) binding of long-acting risperidone administered intramuscularly once a month...
Emerging drugs for schizophreniaOfer Agid
Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
Expert Opin Emerg Drugs 13:479-95. 2008..As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned...
Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndromeTony Cohn
Department of Psychiatry, University of Toronto, and Center for Addiction and Mental Health, Toronto, Ontario
Can J Psychiatry 49:753-60. 2004..To determine the prevalence and characteristics of coronary heart disease (CHD) risk factors in patients with chronic schizophrenia or schizoaffective disorder...
Hyperinsulinemia in psychiatric patients treated with olanzapineTony A Cohn
J Clin Psychiatry 63:75-6. 2002
Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophreniaDonald Addington
Departments of Psychiatry, University of Calgary, Calgary, Alberta, Canada
J Clin Psychopharmacol 22:20-5. 2002..Testing the efficacy of widely accepted but poorly evaluated treatments should be a research priority. Future studies require a larger sample size and longer duration of treatment...
Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary reportTony A Cohn
Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario
Can J Psychiatry 51:382-6. 2006..To compare the insulin sensitivity and adiponectin levels of medication-free patients suffering from schizophrenia or schizoaffective disorder with that of matched healthy volunteers...
Impact of haloperidol, a dopamine D2 antagonist, on cognition and moodHuma Saeedi
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Schizophr Res 85:222-31. 2006..The present results suggest that DA D(2) blockade, as induced by haloperidol, produces important deficits that extend beyond motor or endocrine changes...
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjectsMichael Kiang
Schizophrenia Division, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ont
J Psychiatry Neurosci 28:293-9. 2003..Our results suggest that actigraphy is useful as a sensitive, noninvasive tool for measuring the effect of antipsychotics on spontaneous motor activity...
Predictors and markers of clozapine responseCarmen Chung
Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
Psychopharmacology (Berl) 179:317-35. 2005..Three potential measures were identified: reduction of frontal cortex metabolic activity, reduction of caudate volume, and improvement in P50 sensory gating...
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in ratsPeter Turrone
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
Biol Psychiatry 57:406-11. 2005....
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychoticW Wolfgang Fleischhacker
Department of Biological Psychiatry, Innsbruck University Clinics, Anichstrasse 35, 6020 Innsbruck, Austria
J Clin Psychiatry 64:1250-7. 2003..The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia...
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychoticsJohannes Tauscher
University of Toronto Department of Psychiatry, Schizophrenia Program
Am J Psychiatry 161:1620-5. 2004....
Direct activation of the ventral striatum in anticipation of aversive stimuliJimmy Jensen
PET Centre, Centre for Addiction and Mental Health, Baycrest Geriatric Centre, Toronto, Ontario, Canada
Neuron 40:1251-7. 2003..Our data suggest that the ventral striatum, a crucial element of the brain "reward" system, is directly activated in anticipation of aversive stimuli...
Tardive dyskinesia and iron statusSiow-Ann Chong
J Clin Psychopharmacol 24:235-6. 2004
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidoneDavid Mamo
Department of Psychiatry, University of Toronto, Montreal, Canada
Am J Psychiatry 161:818-25. 2004....
Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesiaTakahiro Shinkai
Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ont, Canada M5T 1R8
Neurosci Lett 388:116-20. 2005..1, p=1.00) were observed between subjects with and without TD. Our results suggest that the GSTP1 gene polymorphism does not confer increased susceptibility to TD, although further studies are warranted before a conclusion can be drawn...
Apathy in schizophrenia: clinical correlates and association with functional outcomeMichael Kiang
Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Schizophr Res 63:79-88. 2003..It was not associated with observed interest in playing a video game or performance on a simulated clerical task...
Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosineDavid Mamo
Department of Psychiatry, University of Toronto, Canada
Synapse 52:153-62. 2004..Our results suggest that 6-[18F]-L-m-tyrosine PET may not be a useful tool in the study of the effect of antipsychotics on dopamine synthesis in human subjects...
Psychometric evaluation of the Readiness for Discharge QuestionnaireSteven G Potkin
University of California, Irvine, Department of Psychiatry and Human Behavior, Brain Imaging Center, Irvine Hall, Room 166, Orange, CA, USA
Schizophr Res 80:203-12. 2005..The psychometric properties of the RDQ are described...
Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in ratsPeter Turrone
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
Neuropsychopharmacology 28:1433-9. 2003..These findings support the contention that D(2) occupancy levels induced by chronic HAL must be high and sustained through the day before significant risk of VCMs, and perhaps also TD, emerges...
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in ratsPeter Turrone
Centre for Addiction and Mental Health, Schizophrenia and Continuing Care Program, 250 College Street, Room 745, Toronto, Ontario, Canada M5T 1R8
Psychopharmacology (Berl) 165:166-71. 2003..A dose-response relationship between dopamine D(2) occupancy and acute extrapyramidal symptoms (EPS) has been well established. However, the link with the induction of tardive dyskinesia (TD) is less clear...
"Extended" antipsychotic dosing: rationale and pilot dataGary Remington
J Clin Psychopharmacol 25:611-3. 2005
Augmenting strategies in clozapine-resistant schizophreniaGary Remington
CNS Drugs 20:171. 2006
Interventions to reduce weight gain in schizophreniaGuy Faulkner
Faculty of Physical Education and Health, University of Toronto, Toronto, Canada
Schizophr Bull 33:654-6. 2007
Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infantsGideon Koren
Division of Clinical Pharmacology Toxicology, The Hospital for Sick Children, Toronto, Ont, Canada
Am J Psychiatry 159:136-7. 2002..Atypical antipsychotics cause various degrees of weight gain. The authors assessed folate status and obesity among patients with schizophrenia receiving atypical antipsychotics...
Remission: what's in a name?Gary Remington
Am J Psychiatry 162:2393-4; author reply 2394. 2005
Validation of a physical activity assessment tool for individuals with schizophreniaGuy Faulkner
Faculty of Physical Education and Health, University of Toronto, 55 Harbord Street, Toronto, Ontario, Canada M5S 2W6
Schizophr Res 82:225-31. 2006..The objective of this study was to provide preliminary validation of the Short-Form International Physical Activity Questionnaire (IPAQ), a measurement tool that could prove useful for both clinicians and researchers in the field...
Overstating the case about recovery?Gary Remington
Psychiatr Serv 56:1022; author reply 1022-3. 2005
